newsfilter
← Latest News
GlobeNewswire·

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization – -- Company to